MR
Michael Rapp
Director

Michael Rapp insider trades: Immunome (IMNM) stock buys and sales

Director, Immunome Last trade Sep 13, 2021 23 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2011
4
Companies
last trade 2021

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Michael reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Sep 13, 2021IMNM↑ Buy$518K
Sep 10, 2021IMNM↑ Buy$830K
May 26, 2021IMNM↑ Buy$983K
Oct 6, 2020IMNM↑ Buy$1000K
May 30, 2018ZYNE↑ Buy$61K
May 2, 2018ZYNE↑ Buy$157K
Mar 22, 2018ZYNE↑ Buy$93K
Jan 2, 2018ZYNE↑ Buy$195K
Oct 23, 2017ZYNE↑ Buy$974K
Dec 29, 2016ZYNE↑ Buy$159K
Oct 16, 2013CCAC↑ Buy$815K
May 27, 2011NONE↓ Sell$7K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other IMNM insiders

Open-market trades in the last 12 months

About Michael Rapp's insider trades

Michael Rapp is a director at Immunome (IMNM). Since May 27, 2011, Michael has reported 11 open-market purchases worth $5.8M and 1 sale worth $7K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (6 filings), other transactions (3 filings), conversions (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMNM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.